Participants eligible for inclusion in this study must meet all of the following criteria: - Men and women aged 18 years or older - Stable NYHA functional class II-III - LVEF <50% - NT-proBNP ≥600 pg/ml if in sinus rhythm or ≥900 pg/ml if in atrial fibrillation at screening - On stable standard of care therapy with sacubitril/valsartan with a dose of at least 49/51 mg BID for at least 4 weeks before screening.

Participants will be deemed ineligible for inclusion if they meet any of the following exclusion criteria: - Acute decompensated heart failure within 3 months prior to screening - SBP <105 mmHg at screening or baseline. - Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, PCI, or carotid angioplasty within the 6 months prior to screening - Hemodynamically significant mitral and/or aortic valve disease, or any prior valve replacement, except mitral regurgitation secondary to LV dilation at screening - eGFR <45 ml/min/1.73m2 at screening, as measured by the CKD-EPI formula - BMI >40 kg/m2 - Strong CYP3A4 inhibitors or inducers, sGC activators (vericiguat), PDE5 inhibitors, and nitroglycerin products - Women of childbearing potential Further eligibility criteria might apply in alignment with the trial protocol.